Welcome to our dedicated page for RIDGETECH SEC filings (Ticker: RDGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ridgetech, Inc. (NASDAQ: RDGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Cayman Islands exempted company and foreign private issuer. Ridgetech files reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934, including Form 20-F annual reports and Form 6-K current reports that describe its wholesale distribution of pharmaceutical and other healthcare products in China.
Through these filings, investors can review how Ridgetech presents its business model and segment information, including its focus on online and offline wholesale distribution and the classification of its historical retail pharmacy operations as discontinued operations under ASC 205. Financial statements contained in these reports provide details on revenues, cost of goods sold, gross profit, operating expenses, income or loss from continuing and discontinued operations, and cash flows from operating, investing and financing activities.
Ridgetech’s 6-K filings also document capital markets transactions and corporate governance matters. Examples include private placements of ordinary shares and warrants with non-U.S. accredited investors, shareholder rights agreements that grant demand and piggyback registration rights, and explanations of how the company relies on Cayman Islands corporate governance practices where permitted by Nasdaq rules. Other filings report the results of annual general meetings, including director elections, auditor ratification, approval of share consolidations and adoption of amended and restated memorandum and articles of association, as well as updates to equity incentive plans.
On Stock Titan, users can see new Ridgetech filings as they are made available from EDGAR and use AI-powered summaries to interpret complex documents. These tools help clarify the implications of Form 20-F disclosures, Form 6-K current reports, registration statements on Forms F-3 and S-8, and other exhibits related to Ridgetech’s financing arrangements and governance structure, making it easier to understand the company’s regulatory and financial reporting history.
Ridgetech, Inc. reports results for the six months ended September 30, 2025, its first period after divesting its retail pharmacy business and focusing on pharmaceutical wholesale in China. Revenue was $62.8 million, essentially flat compared with the prior year, but the mix shifted as offline wholesale revenue decreased while new online platform revenue from Allright contributed $11.1 million. Overall gross profit increased slightly to $2.46 million, with a low total gross margin of about 3.9%, reflecting price competition in offline wholesale and higher margins of about 7.0% in online distribution.
The company moved from net income from continuing operations to a small net loss of $60,167, mainly due to higher selling expenses tied to the expanded online wholesale business. Operating cash flow improved significantly to an inflow of about $5.35 million, and total cash and restricted cash were $18.0 million at period end. Ridgetech relies on bank acceptance notes from Hangzhou United Bank, with a total credit line of approximately $9.73 million and about $5.07 million still available as of September 30, 2025.
Management believes current resources and bank facilities support operations for at least the next 12 months. After period end, on October 30, 2025, the company agreed to a private placement of 4,680,000 ordinary shares at $0.60 per share for gross proceeds of $2,808,000, along with warrants to purchase up to 11,700,000 additional shares at an exercise price of $1.60 per share.
Ridgetech, Inc. reported the results of its annual general meeting held on December 12, 2025. Shareholders elected directors Lingtao Kong, Caroline Wang, Jiangliang He and Genghua Gu, each receiving roughly 4.28 million votes in favor with about 22,000 votes withheld.
Shareholders also approved all other items on the agenda, including ratification of the independent accountants, an ordinary share consolidation, a restatement of the company’s memorandum and articles of association, and a new equity incentive plan. Each proposal passed with about 4.28 million votes cast for and relatively few votes against or abstaining, indicating broad support for the board’s recommendations.
Ridgetech, Inc., a foreign private issuer, submitted a Form 6-K mainly to make a key executive contract part of its existing SEC registration statements. The report is incorporated by reference into Ridgetech’s Form F-3 registration statements (Nos. 333-291941, 333-259692 and 333-269182) and Form S-8 registration statements (Nos. 333-264505, 333-268809 and 333-277849).
The filing lists as an exhibit a CFO Employment Agreement dated August 1, 2024 between Ridgetech and Ming Zhao, provided in English translation. The document is signed on behalf of the company by Ming Zhao in their capacity as Interim Chief Executive Officer and Chief Financial Officer.
Ridgetech, Inc. completed a private placement, selling 4,680,000 ordinary shares at $0.60 per share for aggregate gross proceeds of $2,808,000, and issuing warrants to purchase up to 11,700,000 ordinary shares at a $1.60 exercise price. The warrants are exercisable immediately and expire 36 months from issuance. The transaction closed on November 7, 2025 and relied on Regulation D and Regulation S exemptions.
Investors received demand and piggyback registration rights and agreed, under a Shareholder Rights Agreement, to vote in line with the Board’s recommendations on proposals requiring shareholder approval and to refrain from certain transactions without Company or Board consent.
As a Cayman Islands company and foreign private issuer, Ridgetech followed home country practice and did not seek NASDAQ Listing Rule 5635 shareholder approval for this issuance, as permitted by NASDAQ Listing Rule 5615(a)(3)(A).